RYR1 Genotype

Some people carry a change in one muscle gene that turns common anesthesia drugs into a trigger for rigid muscles, runaway body heat, and muscle breakdown. Nothing in a routine blood panel shows it. In a genetic database of over 62,000 Icelanders, about 1 in 1,450 carried a variant like this that doctors would act on. That figure is on the conservative end. Other estimates run higher, between about 1 in 300 and 1 in 1,000 in some models, so the true number is likely larger than any single population suggests.

This test reads RYR1 (ryanodine receptor 1), the gene most often behind that anesthesia reaction, which is called malignant hyperthermia. The same gene also explains a large share of inherited muscle diseases and some cases of muscle breakdown after hard exercise or heat. You get the answer once, and it matters every time you go under anesthesia for the rest of your life.

What the Gene Actually Does

Every time you move, a nerve signal has to become force. RYR1 carries the instructions for the gate that makes that handoff. The gate is built into a calcium store inside each muscle fiber. When a voltage sensor on the fiber's surface picks up the nerve signal, it pulls the gate open, calcium floods out, and the fiber contracts.

Changes in the gene break that gate in two broad ways. Some make it too eager: it opens too easily or leaks calcium, and the muscle can run hot under stress. Others make the gate too weak, or leave too little of it, so the muscle can't pull with full force. The first pattern drives malignant hyperthermia and exercise-triggered muscle breakdown. The second drives weakness that often shows up from birth.

The gene is enormous. It has 106 coding sections spread across roughly 15,000 letters of code, which is why labs now read the whole thing with next-generation sequencing instead of checking a handful of known trouble spots.

Malignant Hyperthermia

Malignant hyperthermia is a reaction to two kinds of anesthesia drugs: the inhaled gases used to keep you asleep, and a fast-acting muscle relaxant called succinylcholine. The gases are the main trigger. In a susceptible person they throw the gate open. Succinylcholine mostly speeds up and worsens a reaction, and rarely sets one off on its own. Muscles go rigid, metabolism surges, and the body can collapse on the table. Many carriers have little or no weakness day to day, so nothing tips them off beforehand.

The obvious question is how likely a carrier is to actually react. The best data come from families already known to carry a diagnostic variant.

Sources: Ibarra Moreno et al. (rows 1 and 2); Yu et al. (row 3).

These numbers can look like they cancel each other out. They don't. A risk variant is a loaded setup, not a scheduled event: whether it fires depends on the drug, the dose, the person's sex and age, and other genes. The same family study found that a past anesthetic without trouble doesn't rule out a reaction next time, and UK family studies found the gene result and the muscle test sometimes disagreed within the same family. Since no one can tell in advance which carrier will react, a confirmed variant means planning every anesthetic as if you will.

What this means for you: a reaction rate under half across carriers is a population average. For the person who reacts, it's the whole event. Knowing your genotype lets an anesthesia team choose drugs that don't trigger the gate, which removes most of the danger before you're ever wheeled in.

Muscle Breakdown After Exercise or Heat

Rhabdomyolysis is muscle tissue breaking down fast enough to release its contents into the blood. RYR1 variants are a common cause of unexplained rhabdomyolysis and severe aching after exertion. The same gene turns up in people who collapse from heat during hard exercise.

People in this group often look strong. In one series, carriers with exercise-triggered muscle breakdown had bulky muscles and no fixed weakness, and a muscle biopsy often shows nothing specific. A few carriers present later in life with bouts of temporary paralysis instead. Many of them also carry the anesthesia risk, and so can their relatives.

What this means for you: if you've had a bad episode of muscle breakdown after training or heat and were told it was just overdoing it, this gene is worth reading. A positive result changes your surgical safety, not only your training.

Inherited Muscle Diseases

A congenital myopathy is a muscle disease present from birth or early childhood. RYR1 is the single most common gene behind them. In a UK review of 1,927 people tested over ten years, it was the most common cause among the solved congenital myopathy diagnoses. It also ranks among the top genes found in adults with unexplained limb-girdle weakness and in babies with reduced movement before birth.

How the disease looks depends on how it's inherited. One faulty copy usually causes the dominant form, often central core disease, named for the empty-looking cores seen in muscle fibers under a microscope. Two faulty copies, one from each parent, cause recessive forms that start earlier and tend to be more severe, sometimes affecting swallowing and breathing. In a large cohort, recessive variants were as common as dominant ones.

Severity isn't fixed by the gene alone. One recurrent variant caused floppiness in infancy followed by steadily improving strength over the first decades of life. Treatment is still early: in a small first safety trial, a drug designed to stop the gate from leaking was well tolerated and most participants reported less fatigue.

Effects Outside Skeletal Muscle

The gene is also active in the smooth muscle of blood vessels, in the pancreas, and in some immune cells. That explains a set of findings that would otherwise seem unrelated. The evidence here is small: case reports, lab work on patient cells, and one questionnaire study.

• Bleeding: one variant linked to malignant hyperthermia was also tied to abnormal bleeding.
• Pancreatitis: carriers of gate-overactive variants may be at higher risk of acute pancreatitis.
• Immune cells: carriers' antibody-making cells appeared pre-activated, with more allergies reported.
• Pregnancy and gut: among 154 female carriers surveyed, heavier bleeding, pregnancy complications, lower birthweight, and digestive symptoms were more common.

A separate line of research looked at common, everyday versions of this gene rather than the rare disease-causing changes this test is built to find. In 327 people with heart failure, carrying two copies of either of two common versions that change how strongly the gene is switched on was tied to lower risk of death, after adjusting for age, kidney function, heart medications, and other factors. A diagnostic report won't flag those versions, so treat this as background biology rather than something to act on.

Who Carries These Variants

Risk variants aren't limited to one ancestry, but which ones turn up varies. In whole-genome data from 4,810 Singaporeans, several disease-causing and likely disease-causing variants were found, most often in people of Indian descent. In a Black African cohort with an undiagnosed muscle disease, recessive variants in RYR1 and a partner gene called STAC3 were the main cause, after diagnostic delays that ran for decades.

What this means for you: if your ancestry is underrepresented in genetic research, full-gene sequencing matters more, because panels built on European families can miss the variants common in your population.

Why a Single Result Can Mislead

The sequencing itself is accurate. What limits it is what a gene reading can and can't prove.

• A negative result is not an all-clear: in several cohorts of people proven susceptible by muscle testing, sequencing found no causal change in the gene for a large share of them. Other genes, such as CACNA1S and STAC3, explain some of the rest, and some cases stay unexplained.
• Hard-to-read stretches: a couple of the gene's sections sometimes need backup sequencing, and changes deep between the coding sections can be missed unless the whole genome is read. Across 450,000 patients tested for many conditions, about one in seven disease-causing variants was technically hard for standard sequencing to detect.
• Variants of uncertain significance: a variant of uncertain significance is a change the lab can't yet call harmful or harmless. Because the gene is so large, these are common, and computer predictions don't settle them: prediction tools caught most harmful variants but were unreliable at clearing harmless ones.
• Consumer genotyping: in one study of raw data from direct-to-consumer genetic tests, 40% of reported variants were false positives when rechecked in a clinical lab.
• Mosaic parents: a parent can carry the variant in only some of their cells, which can make a family's pattern look confusing and change how severe the disease appears across generations.

A Result You Keep for Life

Your DNA doesn't change, so this is a one-time test. There's no trend to track and no reason to repeat it unless a result came from a consumer test or needs confirming by a second method.

The value comes from using the answer for decades: every surgery, dental sedation, and procedure with anesthesia. If you carry a variant and have muscle symptoms, the thing to follow over time is your muscles, not the gene. A blood test for creatine kinase (the enzyme muscles release when damaged) during or after an episode shows whether breakdown is happening, though a normal resting level is common in carriers.

What to Do With Your Result

A disease-causing or likely disease-causing variant: put it in every medical record and tell every anesthesia team before any procedure, so they choose drugs that don't trigger the gate. Your parents, siblings, and children should be tested for the same variant. If you have weakness, exercise-triggered symptoms, or muscle breakdown episodes, see a neuromuscular specialist.

A variant of uncertain significance: don't read it as a diagnosis or as an all-clear. Testing relatives to see whether the variant tracks with symptoms or reactions in your family can settle it, and a specialist malignant hyperthermia center can run a muscle contracture test, which exposes a small muscle sample to trigger drugs. Until then, tell your anesthesia team; a trigger-free anesthetic is a reasonable precaution.

A negative result with a strong personal or family history of an anesthesia reaction: the contracture test is still the reference standard, and a broader panel covering CACNA1S and STAC3 is worth adding. Two variants found together, with muscle symptoms, calls for a genetic counselor and testing both parents to confirm whether they sit on opposite copies of the gene.